SCHEMBL6859637

SCHEMBL6859637

C[C@H](NC(=O)C=Cc1ccccc1)c1cccc(-c2cnccn2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.59
PIM2 Q9P1W9 1/20 0.58
LMNA P02545 1/20 0.51
CYP2C9 P11712 2/20 0.51
KCNQ3 O43525 1/20 0.51
KCNQ2 O43526 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP19A1 P11511 1/20 0.51
GSK3B P49841 1/20 0.45
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LDHA P00338 1/20 0.43
LDHB P07195 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HSP90AA1 P07900 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859634 1.00 TDP1 (0.59) TDP1PIM2LMNACYP2C9KCNQ3
SCHEMBL6859640 1.00 TDP1 (0.59) TDP1PIM2LMNACYP2C9KCNQ3
SCHEMBL6647292 0.88 TDP1 (0.63) TDP1LMNACYP2C9KCNQ3KCNQ2
SCHEMBL6625980 0.88 TDP1 (0.63) TDP1LMNACYP2C9KCNQ3KCNQ2
SCHEMBL30794838 0.88 TDP1 (0.63) TDP1LMNACYP2C9KCNQ3KCNQ2
SCHEMBL6647302 0.88 TDP1 (0.63) TDP1LMNACYP2C9KCNQ3KCNQ2
SCHEMBL6647298 0.88 TDP1 (0.63) TDP1LMNACYP2C9KCNQ3KCNQ2
SCHEMBL6669350 0.86 PIM2 (0.44) TDP1PIM2LDHALDHB
SCHEMBL30795152 0.86 PIM2 (0.44) TDP1PIM2LDHALDHB
SCHEMBL6669339 0.86 PIM2 (0.44) TDP1PIM2LDHALDHB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831080-B2 E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents BRISTOL-MYERS SQUIBB COMPANY 2004-12-14 US disclosed